Immunome (IMNM) Common Equity (2019 - 2026)

Immunome's Common Equity history runs 8 years deep, the most recent figure standing at $588.7 million for Q1 2026.

• Quarterly Common Equity rose 91.68% year-over-year to $588.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $588.7 million (up 91.68% YoY) and the FY2025 annual result came in at $634.3 million, up 250.15% from the prior year.
• Common Equity was $588.7 million for Q1 2026 at Immunome, down from $634.3 million in the prior quarter.
• Across five years, Common Equity topped out at $634.3 million in Q4 2025 and bottomed at $6.1 million in Q3 2023.
• A 5-year average of $191.5 million and a median of $181.2 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity tumbled 73.68% — and 2024, when it surged 3436.97%.
• Immunome's Common Equity stood at $16.7 million in 2022, then surged by 619.88% to $119.9 million in 2023, then soared by 51.12% to $181.2 million in 2024, then jumped by 250.15% to $634.3 million in 2025, then dropped by 7.2% to $588.7 million in 2026.
• Business Quant data shows IMNM's Common Equity at $588.7 million in Q1 2026, $634.3 million in Q4 2025, and $263.9 million in Q3 2025.